TGTX: H.C. Wainwright Maintains Buy Rating, May 2026

H.C. Wainwright maintained its Buy rating on TG Therapeutics (TGTX) while raising the price target to $70 from $60, signaling confidence in the biotech firm’s pipeline. The TGTX analyst rating reflects strong momentum following the company’s earnings announcement on May 6, 2026. TGTX stock surged 16.26% to $41.97, driven by positive clinical progress and commercial execution. The $6.7 billion market cap biotech company focuses on B-cell malignancies and autoimmune diseases. This TGTX analyst rating maintains bullish sentiment despite broader market volatility in the healthcare sector.

H.C. Wainwright Maintains Buy Rating on TGTX

Price Target Raised to $70

H.C. Wainwright raised the TGTX price target to $70 from $60, maintaining its Buy rating on the stock. This 17% upside from current levels reflects analyst confidence in the company’s clinical pipeline and commercial momentum. The price target increase came after TG Therapeutics reported earnings on May 6, 2026, which exceeded expectations. The TGTX analyst rating now positions the stock for potential gains as key programs advance through development stages.

Strong Earnings Catalyst

TG Therapeutics delivered solid earnings results that justified the price target increase. The company’s revenue grew 87% year-over-year, demonstrating strong commercial traction for its approved therapies. Net income surged 18.1% annually, showing improving profitability as the company scales operations. The TGTX analyst rating reflects these operational improvements and the potential for sustained growth in coming quarters.

Stock Performance and Technical Strength

Momentum Builds Post-Earnings

TGTX stock jumped 16.26% on the earnings announcement, closing at $41.97 with volume reaching 6.6 million shares. The stock has now gained 40.8% year-to-date, significantly outperforming many biotech peers. Technical indicators show strong momentum, with the RSI at 73.88 indicating overbought conditions but also reflecting genuine buying interest. The TGTX analyst rating upgrade supports this bullish technical setup.

Analyst Consensus Strengthens

Three analysts now rate TGTX as Buy, with one Hold rating, creating a consensus score of 3.0 out of 5. This TGTX stock consensus reflects broad support for the company’s strategic direction. The average price target of $70 suggests 67% upside from the May 6 closing price of $38.25. The TGTX analyst rating environment remains constructive as more firms recognize the company’s competitive advantages.

Pipeline Progress and Commercial Execution

Key Programs Advancing

TG Therapeutics’ pipeline includes Ublituximab for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia, plus Umbralisib for multiple lymphoma types. The company also develops Cosibelimab targeting PD-L1 and TG-1701, a selective BTK inhibitor. These programs address large addressable markets with limited competition. The TGTX analyst rating reflects confidence in these assets reaching peak sales potential.

Meyka AI Stock Grade

Meyka AI rates TGTX with a grade of B+, reflecting strong fundamentals and growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s return on equity of 101% and strong gross margins of 84% support this positive assessment. These grades are not guaranteed and we are not financial advisors.

Valuation and Risk Factors

Reasonable Valuation Metrics

TGTX trades at a forward P/E of 13.2x, below the biotech sector average, offering attractive entry points for growth investors. The price-to-sales ratio of 10.7x reflects premium pricing but justified by 87% revenue growth. The company maintains a strong balance sheet with $4.1x current ratio and minimal debt. The TGTX analyst rating acknowledges these favorable valuation dynamics.

Execution Risks Remain

While the TGTX analyst rating is positive, clinical trial risks persist for pipeline programs. Regulatory approvals are never guaranteed, and competitive pressures from larger pharma companies could impact market share. The company’s negative free cash flow of $0.17 per share requires careful monitoring. However, H.C. Wainwright’s maintained Buy rating suggests these risks are manageable given the company’s cash position and revenue growth trajectory.

Final Thoughts

H.C. Wainwright’s maintained Buy rating and raised price target to $70 underscore confidence in TG Therapeutics’ strategic positioning within oncology and immunology. The TGTX analyst rating reflects strong earnings execution, robust pipeline progress, and attractive valuation relative to growth prospects. With three Buy ratings and one Hold, consensus support remains solid. The stock’s 16% post-earnings surge validates the positive sentiment. Investors should monitor upcoming clinical data and commercial milestones. The TGTX analyst rating environment appears constructive, though execution risks warrant careful attention to quarterly results and pipeline updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.